Fig. 2

Flowchart of the REMORA2 feasibility trial domains (1) Recruitment and consent, (2) Intervention Uptake: “On-boarding” and (3) Intervention Adherence: “Completeness of symptom tracking”. Low adherers—symptoms reported on <25% days; Moderate adherers—symptoms reported on 25–60% days; High adherers—symptoms reported on >60% days. *We were unable to collect data on people who were excluded after screening as we did not have their consent to do this; **Some reasons for declining participation, explored during ‘decliner interviews’ can be found in Table 4; ***Includes one participant who withdrew after 9 days but was classified as a high engager while in the study